Health Technology Assessment in Pharma: A Review of Major Decisions

May 2020| PHM228A| BCC Publishing

Report Highlights

The goal of this study is to provide information on the global health technology approval process in North America, Europe and the Asia-Pacific region. The study emphasizes the role of HTA and its function and technology process in the pharmaceutical industry. The report also elaborates on recent HTA approvals and their significance on pricing and reimbursement.

Report Includes

  • 45 tables
  • A detailed outlook on the HTA process and its approvals in major pharma industries
  • Insights into the recent HTA submissions to HTA agencies by top pharmaceutical manufacturers
  • Discussion on how HTA helps in the development of safe, and effective health policies, thereby benefitting both patient and health care providers
  • Information about the medical, social, economic and ethical issues related to the use of a health technology
  • Company profiles of market-leading players, including Janssen Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Co., and Hofmann-La Roche Inc.

Report Scope

The current report provides details about HTA processes in countries such as U.S., Canada and U.K. This report highlights information and insights on the molecules which were recently approved in terms of regulatory and reimbursement decisions. The report includes policies, country-specific HTA activities, drug overviews, mechanisms of action, disease backgrounds, clinical evidence on safety and efficacy, regulatory scenarios, and HTA evaluation details.

Frequently Asked Questions (FAQs)

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Latest reports include:

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesMember Price
Full Report: Health Technology Assessment in Pharma: A Review of Major Decisions82Free
Chapter- 1: Introduction3Free
Chapter- 2: Introduction to Health Technology Assessment4Free
Chapter- 3: Pharmaceutical Industry’s Perspective on HTA2Free
Chapter- 4: Overview of Global HTA Organizations39Free
Chapter- 5: Daratumumab (Darzalex)7Free
Chapter- 6: Tildrakizumab (Ilumya)5Free
Chapter- 7: Durvalumab (Imfinzi)7Free
Chapter- 8: Abemaciclib (Verzenio)7Free
Chapter- 9: Ocrelizumab (Ocrevus)7Free
Chapter- 10: Conclusion1Free
Health Technology Assessment in Pharma: A Review of Major Decisions

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries